Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PAFSC First Committee to Review Glatiramer, Add’l Indication for Xarelto on Aug. 28
August 17, 2015
- Editor’s Pick: Five Healthcare News Headlines for July 21 - August 9
August 10, 2015
- MHLW Notifies of Package Insert Changes for Daklinza, Sunvepra
August 10, 2015
- “Greater Emphasis” Will Need to Be Placed on R&D in Field of Oncology: AMED President
August 7, 2015
- MHLW Calls for Package Insert Revision for Inavir, Relenza
August 7, 2015
- Health Minister Reviewing Ways to Strengthen Guidance to Optimize Ethical Drug Ads: Senior Vice Minister Nagaoka
August 6, 2015
- PAFSC 2nd Committee Endorses Approval of AZ’s Vandetanib
August 5, 2015
- Lupus Nephritis to Be Added to Cellcept’s Indication: MHLW Notification
August 4, 2015
- PAFSC’s First Committee Supports Approval of Actelion’s Tracleer for Digital Ulcers in Generalized Scleroderma
August 3, 2015
- AMED Sets Up 5-Step Process to Pick Licensees of Academic Drug Seeds
July 30, 2015
- MHLW to Continue Discussions on Elderly Use of Prevenar 13 under National Vaccination Program
July 29, 2015
- Finance Minister Calls for Revision of Special Measures on Taxation “Without Preconceptions”
July 28, 2015
- Government Approves Basic Policy on Budget Requests for FY2016
July 28, 2015
- ICH Assembly to Make Final Decisions on All Important Issues: PMDA Official
July 27, 2015
- Japan Embarking on Biosimilar Development, but It’s a Race against Time: MHLW Official
July 24, 2015
- Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015
- Chuikyo Subcommittee OKs Plan to Draft GL for Analyzing Cost-Effectiveness; QALY Expected to Be Main Index
July 24, 2015
- Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
July 23, 2015
- Kaketsuken Withdraws Earlier Explanation of Blood Products Scandal; Problem Discovered through Information Provided to MHLW
July 23, 2015
- AMED Takes Initial Step Toward Out-Licensing First Lead Compound; Now Taking Applications from Companies
July 23, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…